Orbix Medical

Minimally Invasive Solutions for Breast Surgery

Health Tech & Life Sciences
Non Active, Oct 2018

Company Overview

Snapshot

Founded in October 2004 by Eyal Gur, Orbix Medical operates with 1–10 employees. The company focuses on medical devices for breast plastic surgery, achieving a significant milestone in November 2013 by receiving CE Mark approval for its "internal bra" technology.

Business overview

Orbix Medical develops, manufactures, and commercializes medical devices for breast plastic surgery procedures. Its core products, OrbiShape and OrbiSymm, are CE-marked systems designed to enhance outcomes in mastopexy, reduction, and symmetrization. The OrbiShape system specifically supports breast tissue to prevent sagging and maintain aesthetic results over time. The company operates within the Health Tech & Life Sciences sector, focusing on medical devices and aesthetic treatments for healthcare providers and women.

Strategic signal

In November 2013, Orbix Medical received CE Mark approval for its "internal bra" technology. This regulatory clearance was a critical validation for the company's OrbiShape and OrbiSymm devices, signaling market readiness and enabling commercialization within Europe. For investors, this milestone demonstrated the company's ability to navigate medical device regulations and bring innovative solutions to the aesthetic surgery market.

Company Intelligence Q&A

What are Orbix Medical's primary medical devices?
Orbix Medical's primary medical devices are OrbiShape and OrbiSymm. These CE-marked systems are designed to improve outcomes in breast plastic surgery procedures such as mastopexy, reduction, and symmetrization.
When did Orbix Medical receive CE Mark approval for its "internal bra" technology?
In November 2013, Orbix Medical received.
What is the core function of the OrbiShape system?
The OrbiShape system is designed to support and bear the weight of breast tissue. Its primary function is to prevent the recurrence of sagging and ensure a satisfactory aesthetic appearance over time following breast procedures.
What was a notable event regarding the OrbiShape system in June 2014?
In June 2014, a successful live surgery using the OrbiShape Breast Supporting System was conducted at CATBBAS 14 by Prof. Moustapha Hamdi, demonstrating its application and effectiveness.
Which markets does Orbix Medical primarily target with its products?
Orbix Medical primarily targets the European market with its medical devices, as indicated by its CE Mark approval.

External links